Cite
HARVARD Citation
Redondo, A. et al. (n.d.). O025/#522 Maintenance olaparib rechallenge in patients with ovarian cancer previously treated with a parp inhibitor: patient-reported outcomes from the phase IIIB OReO/engot-ov38 trial. International journal of gynecological cancer. p. A15. [Online].